ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -15 مورد

Oral budesonide formulations used in treatment of inflammatory bowel disease

Oral budesonide formulations used in treatment of inflammatory bowel disease
Brand names Type Description pH release Delivery Uses
  • Entocort (Canada, US)*
  • Entocort CR (EU, UK), Entocir (EU)

NOTE: Generic equivalents may be available

 Controlled ileal release (CIR) formulation, pH- and time-dependent
  • Entocort, Entocort CR, Entocir:
    • 3 mg gelatin capsule filled with enteric-coated granules
 ≥5.5 Terminal ileum and/or ascending colon Mild to moderately active Crohn of ileum and/or ascending colon
  • Budenofalk (EU, UK, other areas)

NOTE: Not available in US or Canada

 pH-dependent release
  • 3 mg gelatin capsule filled with enteric-coated granules
  • 9 mg sachet filled with enteric-coated granules
 >6.4 Terminal ileum and/or ascending colon Mild to moderately active Crohn of ileum and/or ascending colon
  • Uceris (US)
  • Cortiment (Canada, EU, UK, other areas)
 Multi-matrix (MMX) structure with gastric acid-resistant coating
  • 9 mg delayed- and extended-release tablet
 ≥7.0 Controlled delivery to ascending, transverse, and descending colon Mild to moderately active ulcerative colitis
Orally administered budesonide has high presystemic clearance and topical antiinflammatory activity.

EU: European Union; UK: United Kingdom; US: United States.

* Entocort brand is no longer marketed in the US; a generic equivalent is available.

Adapted from: Iborra M, Alvarez-Sotomayor D, Nos P. Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis. Clin Exp Gastroenterol 2014;7:39.

Additional data from:

  1. US FDA approved drug product information. Available at https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on November 18, 2024).
  2. Electronic Medicines Compendium (eMC UK) Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc (Accessed on November 18, 2024).
Graphic 116034 Version 4.0